Bergen, Norway

BerGenBio is a clinical-stage, biopharmaceutical company based in Bergen, Norway and Oxford, UK. It is developing innovative therapies for aggressive cancers by way of inhibiting the AXL signalling pathway. The lead oncology compound, bemcentinib, is in multiple Phase II trials.

Investment Perspective

In an oral presentation at SITC, new results from Cohort A of the Phase II NSCLC trial with BerGenBio’s selective AXL inhibitor bemcentinib and pembrolizumab confirms the potential of the combination. 90% of the 44 evaluable patients in the cohort had PD-L1 low/negative tumours, and yet the objective response rate (ORR) was 25%; <10% would have been expected with pembrolizumab monotherapy. In those patients, who were AXL+ using a new composite score, the ORR was 33% compared to 7% in those classed as AXL-. Cohort A is in immuno-oncology (IO) naïve patients, and there are also two other cohorts in IO-refractory patients ongoing, the results of which will determine the design of the randomised Phase II study planned to start in 2020. We maintain our valuation of BerGenBio at NOK3.21bn (NOK53.13/share).

Market information

SymbolPrimary exchanges


ASH data continues to support AML potential
Lighthouse | 10 Dec 2019
Bemcentinib NSCLC data continues to impress
Update | 19 Nov 2019
Refining the route ahead
Lighthouse | 20 Aug 2019

Recent News

Q319 report
19 Nov 2019
Clinical data from Phase II combination trial of bemcentinib and LDAC trial in elderly AML to be presented at ASH 2019
07 Nov 2019
Bemcentinib meets primary endpoint in first cohort of Phase II NSCLC combination study with Keytruda
06 Nov 2019
FDA Fast Track designation for bemcentinib in elderly relapsed AML
22 Oct 2019